Becton, Dickinson and Company (NYSE:BDX) Shares Bought by Marks Group Wealth Management Inc

Marks Group Wealth Management Inc grew its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 18.8% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 43,129 shares of the medical instruments supplier’s stock after acquiring an additional 6,823 shares during the period. Becton, Dickinson and Company comprises about 1.0% of Marks Group Wealth Management Inc’s investment portfolio, making the stock its 19th biggest holding. Marks Group Wealth Management Inc’s holdings in Becton, Dickinson and Company were worth $9,879,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Brighton Jones LLC grew its stake in shares of Becton, Dickinson and Company by 98.2% during the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after acquiring an additional 877 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its stake in shares of Becton, Dickinson and Company by 50.6% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 82,110 shares of the medical instruments supplier’s stock valued at $18,808,000 after acquiring an additional 27,581 shares in the last quarter. Foster Victor Wealth Advisors LLC acquired a new stake in shares of Becton, Dickinson and Company during the first quarter valued at about $6,406,000. GAMMA Investing LLC grew its stake in shares of Becton, Dickinson and Company by 29.9% during the first quarter. GAMMA Investing LLC now owns 3,250 shares of the medical instruments supplier’s stock valued at $744,000 after acquiring an additional 748 shares in the last quarter. Finally, Ritholtz Wealth Management acquired a new stake in shares of Becton, Dickinson and Company during the first quarter valued at about $224,000. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP David Shan sold 1,166 shares of the firm’s stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $171.19, for a total value of $199,607.54. Following the sale, the executive vice president owned 4,575 shares in the company, valued at approximately $783,194.25. This trade represents a 20.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.36% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on BDX shares. Piper Sandler downgraded Becton, Dickinson and Company from an “overweight” rating to a “neutral” rating and lowered their target price for the company from $260.00 to $185.00 in a research note on Friday, May 2nd. Raymond James Financial cut shares of Becton, Dickinson and Company from an “outperform” rating to a “market perform” rating in a research report on Friday, May 2nd. Wells Fargo & Company cut shares of Becton, Dickinson and Company from an “overweight” rating to an “equal weight” rating in a research report on Thursday, May 1st. Bank of America cut shares of Becton, Dickinson and Company from a “buy” rating to a “neutral” rating and set a $190.00 price target on the stock. in a research report on Thursday, May 1st. Finally, Citigroup cut shares of Becton, Dickinson and Company from a “strong-buy” rating to a “hold” rating and reduced their price target for the stock from $217.00 to $185.00 in a research report on Thursday, May 22nd. Eight analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $219.22.

Becton, Dickinson and Company Stock Performance

Shares of NYSE BDX opened at $175.87 on Friday. The company has a quick ratio of 0.64, a current ratio of 1.13 and a debt-to-equity ratio of 0.70. The firm’s 50-day moving average price is $172.33 and its two-hundred day moving average price is $205.91. Becton, Dickinson and Company has a 52-week low of $163.33 and a 52-week high of $251.99. The stock has a market capitalization of $50.41 billion, a P/E ratio of 33.56, a P/E/G ratio of 1.33 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.28 by $0.07. Becton, Dickinson and Company had a net margin of 7.28% and a return on equity of 15.99%. The firm had revenue of $5.27 billion for the quarter, compared to analysts’ expectations of $5.35 billion. During the same quarter last year, the company posted $3.17 earnings per share. Becton, Dickinson and Company’s revenue was up 4.5% on a year-over-year basis. As a group, sell-side analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, June 30th. Shareholders of record on Monday, June 9th were paid a $1.04 dividend. The ex-dividend date was Monday, June 9th. This represents a $4.16 annualized dividend and a dividend yield of 2.37%. Becton, Dickinson and Company’s payout ratio is currently 79.39%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.